Date: 27.01.2021

BSE Limited P.J. Towers, Dalal Street Mumbai - 400001

National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400051

Dear Sir/ Madam,

Sub: Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers)
Regulations, 2011 and Regulation 7(2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

Unit: Ortin Laboratories Limited

With reference to the subject cited, I, Sanka Rajeshwari belonging to promoter group, would like to bring to your notice that pursuant to scheme of Arrangement between Ortin Laboratories Limited (Demerged Company) and Vineet Laboratories Limited (Resulting Company) my holding has been changed from 39,110 Equity shares (0.23%) to 18,772 Equity Shares (0.23%). In this regard, I enclose herewith prescribed Form 29 (2) under Regulation 29 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and Form C under Regulation 7(2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,

Sky www and Sanka Rajeshwari

Encl: As above

CC: Ortin Laboratories Limited

Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1.	Name of the Target Company (TC)	Ortin Laboratories Limited		
2.	Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Sanka Rajeshwari		
3.	Whether the acquirer belongs to Promoter/Promoter group	Yes		
4.	Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited National Stock Exchange of India Limited		
5.	Details of the acquisition / disposal/holding of shares/voting rights/holding of the Acquirer and PAC	Number	% w.r.t. total share/voti ng capital wherever applicable	% w.r.t. total diluted share/voting capital of the TC(*)
Be	efore the disposal of shares, holding of:			
	a) Shares carrying voting rights	39110	0.23	0.23
	b) Voting rights (VR) otherwise than by shares	-	=	-
	c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T	-	-	-
	C (specify holding in each category)			
Т	otal (a+b+c)	39110	0.23	0.23
D	etails of disposal of shares			
	a) Shares carrying voting rights acquired	20338	0.00	0.00
	b) VRs acquired /sold otherwise than by shares	_		
	c) Warrants/convertible securities/any other instrument			1

that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	-		_
Total (a+b+c)	20338	0.00	0.00
After the disposal of shares, holding of:			
a) Shares carrying voting rights	18772	0.23	0.23
b) VRs otherwise than by shares	-	-	
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition.		-	
Total (a+b+c)	18772	0.23	0.23
 Mode of sale (e.g. open market / off- market / public issue / rights issue / preferential allotment / inter-se transfer etc). 	Pursuant to Scheme of Arrangement between Ortin Laboratories Limited(Demerged Company) and Vineet Laboratories Limited (Resulting Company)sanctioned by Hon'ble National Company law Tribunal		
 Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable 	23.01.2021		
 Equity share capital / total voting capital of the TC before the said acquisition / sale 	1,69,40,400 equity shares		
 Equity share capital/ total voting capital of the TC after the said acquisition / sale 	81,31,392 equity shares		
 Total diluted share/voting capital of the TC after the said acquisition/sale. 	81,31,392 equity shares		

^(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Signature

Place: Hyderabad Date: 27.01.2021